Partner Headlines - TEVA

  1. Benzinga's M&A Chatter for Tuesday November 18, 2014

    Benzinga
  2. Here Are The Top 25 Analysts On Wall Street

    Benzinga
  3. Insys Q3 Beats Estimates, Helping Stock Rebound

    IBD
  4. Investors Rewarded With Treats, Not Tricks, As Dow And S&P Close ...

    Benzinga
  5. Teva ups full-year EPS outlook

    IBD
  6. UPDATE: Teva Posts Stronger-Than-Expected Q3 Profit, Lifts Forecast

    Benzinga
  7. Earnings Scheduled For October 30, 2014

    Benzinga
  8. Lannett Co. Gets Growth Rx In Generic Drugs Group

    IBD
  9. IPO Calendar: Biotech Companies Lead List Of 7 IPOs

    IBD
  10. Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With ...

    Benzinga
  11. Drugmaker M&A Goes On, With Or Without Tax Inversions

    IBD
  12. Actavis Finds Rx To Grow On Busy Drugmaker M&A Scene

    IBD
  13. Teva Reports Results of Strategic Review, Sees 14 Pipeline Projects ...

    Benzinga
  14. Fast Money Halftime Report Final Trade From October 2 - Twitter ...

    Benzinga
  15. Insys Therapeutics Up On Bullish Analyst Initiation

    IBD
  16. Teva Announces UK High Court Gives Positive Judgment In The Company's ...

    Benzinga
  17. 4 Biotechs That Might Be Bought Soon

    IBD
  18. Notable Hedge Funds Disclose Additions And Reductions To Holdings

    Benzinga
  19. Jana Partners LLC Files its 13F

    Benzinga
  20. Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With ...

    Benzinga
  21. Novo Nordisk, Mylan Miss Views; Mallinckrodt Beats

    IBD
  22. Did George Soros Sell His Stake In Israeli Based SodaStream Due ...

    Benzinga
  23. 5 Drug Companies Profiting From Generics

    Benzinga
  24. Top 5 Earnings Reports To Watch After The Close Tue.

    IBD
  25. Pfizer, Merck, Amgen Near Q2 Earnings Reports

    IBD
  26. George Soros Reveals His Largest Stake

    GuruFocus
  27. Sofinnova Ventures Closes $500M Fund

    FoxBusiness
  28. Israel's Market Appears Unfazed By Rising Conflict

    IBD
  29. George Soros Keeps Buying TEVA, EQT, YPF, EGN, CZR And Keeps ...

    GuruFocus
  30. UPDATE: Teva Announces FDA Acceptance of NDA For Inhaler

    Benzinga
  31. 4 Top Performing Health Care Stocks With More Potential Upside

    Benzinga
  32. Salix, Akorn, Regeneron Lead Drug Stock Rally

    IBD
  33. Top 4 Stocks In The Drug Manufacturers-Other Industry With The ...

    Benzinga
  34. Diamond Hill Capital Comments on Teva Pharmaceutical Industries ...

    GuruFocus
  35. Diamond Hill Select Fund Commentary - First Quarter 2014

    GuruFocus
  36. Teva Pharmaceutical

    IBD
  37. Generic-Drug Makers Climb Ranks; Several In Buy Range

    IBD
  38. Teva Turmoil: Shares Up, Board Trimmed, CEO To Retire

    Benzinga
  39. Wells Fargo Initiates Coverage On The Pharmaceutical Space

    Benzinga
  40. Top Guru Held Asian Companies of the First Quarter

    GuruFocus
  41. Teva to buy Labrys Biologics

    IBD
  42. Chicago sues painkiller firms

    IBD
  43. Benzinga's M&A Chatter for Tuesday June 3, 2014

    Benzinga
  44. Teva Acquiring Labrys Biologics For Migraine Drug

    IBD
  45. Richard Snow's Top Five Highlight Finance and Healthcare Sectors

    GuruFocus
  46. Benzinga's M&A Chatter for Wednesday May 7, 2014

    Benzinga
  47. ETF Outlook For Tuesday May 6, 2014 (EUFN, ITA, EIS, UAE)

    Benzinga
  48. Wrong Marketing Lesson by Big Pharma

    GuruFocus
  49. Sterne Agee Sees Mixed Factors For Teva Pharmaceutical Industries ...

    Benzinga
  50. Teva EPS tops; rivals seen?

    IBD
  51. Market Wrap For May 1: Markets Mixed To Start The New Month

    Benzinga
  52. Earnings Scheduled For May 1, 2014

    Benzinga
  53. Actavis Beats Q1 Views, Looks To Supersized Future

    IBD
  54. Actavis Reporting Q1 Earnings Amid Merger Frenzy

    IBD
  55. US Stock Futures Up Ahead Of Earnings, Consumer Confidence Data

    Benzinga
  56. Morning Market Losers

    Benzinga
  57. Benzinga's Top #PreMarket Losers

    Benzinga
  58. UPDATE: Teva, Oncogenex Offer Top-Line Survival Results of Phase ...

    Benzinga
  59. Nasdaq Could Be in for a Bounce

    FoxBusiness
  60. Actavis got a Pfizer

    IBD
  61. Teva Settles Patent Litigation with Pfizer on Celebrex; Has Received ...

    Benzinga
  62. Sterne Agee Sees Teva Pharmaceutical Outperformance Continuing

    Benzinga
  63. Teva Unveils Generic Lunesta Tablets in US

    Benzinga
  64. Teva Announces First Approval and Launch of Generic Lovaza® Capsules ...

    Benzinga
  65. Market Wrap For April 7: Bears In Complete Control As Markets ...

    Benzinga
  66. Citigroup Slaps $70 Price Target on Teva, Highest on Street

    Benzinga
  67. Market Wrap For March 31: Stocks Rally As Yellen Confirms Support ...

    Benzinga
  68. Analyst Offers Insight on Favorable FDA Ruling for Teva Pharma

    Benzinga
  69. Market Wrap For March 28: Markets Still Positive Despite Giving ...

    Benzinga
  70. Teva Offers Most Attractive Risk-Reward Profile, Citigroup Says

    Benzinga
  71. UPDATE: Goldman Sachs Upgrades Teva Pharmaceutical Industries

    Benzinga
  72. Forest Laboratories' Recovery

    GuruFocus
  73. Should You Buy Actavis?

    GuruFocus
  74. Horizon Pharma Banks On Two-For-One Arthritis Drugs

    IBD
  75. UPDATE: JP Morgan Upgrades Teva Pharmaceuticals

    Benzinga
  76. UPDATE: Morgan Stanley Upgrades Teva Pharmaceutical Industries ...

    Benzinga
  77. Benzinga's Top Upgrades

    Benzinga
  78. US Stock Futures Edge Higher Ahead Of Consumer Sentiment Report

    Benzinga
  79. Pfizer Loses Patent On Celebrex, Plans To Appeal

    IBD
  80. Pfizer Loses Bid to Hold Celebrex Exclusivity to '15

    FoxBusiness
  81. Will Horizon Pharma Spike Again On Quarterly Report?

    IBD
  82. UPDATE: Barclays Upgrades Teva Pharmaceutical Industries Limited ...

    Benzinga
  83. Teva upgraded on drug launch

    IBD
  84. Teva Upgraded On Strong Launch Of Next-Gen Copaxone

    IBD
  85. Weekly 52-Week Highs Highlight: COV, EQT, XLNX, TEVA

    GuruFocus
  86. UPDATE: CRT Capital Initiates Coverage on OncoGenex

    Benzinga
  87. Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With ...

    Benzinga
  88. Insys Recovers From Stock Hit Tied To Fed Probe

    IBD
  89. Generic-Drug Makers Actavis, Mylan To Report Q4 Soon

    IBD
  90. #PreMarket Primer: Friday, February 7: Jobs Friday

    Benzinga
  91. Teva Pharmaceuticals A Giant In Generic Drugs

    IBD
  92. UPDATE: Teva Pharmaceutical Posts Upbeat Q4 Earnings

    Benzinga
  93. Earnings Scheduled For February 6, 2014

    Benzinga
  94. Market Wrap For January 29: Markets Lower on Fed Taper, Emerging ...

    Benzinga
  95. Stocks Hitting 52-Week Highs

    Benzinga
  96. Special Situations Alert: Details Behind Why I Bought PATH

    GuruFocus
  97. Teva, Active Biotech Say Remain Committed to Development of NERVENTRA

    Benzinga
  98. Benzinga's M&A Chatter for Tuesday January 21, 2014

    Benzinga
  99. NuPathe Terminates Agreement With Endo Pharma and Enters Into ...

    Benzinga
  100. US Stock Futures Up; Alcoa Earnings, Jobless Claims Data In Focus

    Benzinga
Trading Center